New England Research & Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $318K | Hold |
605
| – | – | 0.15% | 128 |
|
|
2025
Q1 | $384K | Buy |
+605
| New | +$384K | 0.2% | 114 |
|
|
2023
Q3 | – | Sell |
-940
| Closed | -$675K | – | 166 |
|
|
2023
Q2 | $675K | Buy |
+940
| New | +$675K | 0.39% | 78 |
|
|
2022
Q4 | – | Sell |
-932
| Closed | -$642K | – | 173 |
|
|
2022
Q3 | $642K | Sell |
932
-59
| -6% | -$40.6K | 0.4% | 82 |
|
|
2022
Q2 | $586K | Buy |
991
+45
| +5% | +$26.6K | 0.34% | 102 |
|
|
2022
Q1 | $661K | Sell |
946
-29
| -3% | -$20.3K | 0.34% | 89 |
|
|
2021
Q4 | $616K | Buy |
975
+360
| +59% | +$227K | 0.3% | 101 |
|
|
2021
Q3 | $372K | Sell |
615
-1,045
| -63% | -$632K | 0.19% | 127 |
|
|
2021
Q2 | $927K | Sell |
1,660
-200
| -11% | -$112K | 0.48% | 74 |
|
|
2021
Q1 | $880K | Buy |
1,860
+725
| +64% | +$343K | 0.48% | 72 |
|
|
2020
Q4 | $548K | Sell |
1,135
-470
| -29% | -$227K | 0.34% | 95 |
|
|
2020
Q3 | $898K | Buy |
+1,605
| New | +$898K | 0.65% | 52 |
|
|
2017
Q1 | – | Sell |
-730
| Closed | -$268K | – | 184 |
|
|
2016
Q4 | $268K | Sell |
730
-125
| -15% | -$45.9K | 0.21% | 139 |
|
|
2016
Q3 | $344K | Sell |
855
-290
| -25% | -$117K | 0.29% | 112 |
|
|
2016
Q2 | $400K | Buy |
1,145
+170
| +17% | +$59.4K | 0.34% | 103 |
|
|
2016
Q1 | $351K | Buy |
+975
| New | +$351K | 0.3% | 110 |
|
|
2014
Q1 | – | Sell |
-2,498
| Closed | -$688K | – | 154 |
|
|
2013
Q4 | $688K | Buy |
+2,498
| New | +$688K | 0.66% | 51 |
|